Pelabresib + Ruxolitinib + Placebo

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Myelofibrosis

Conditions

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

Trial Timeline

Apr 9, 2021 → Jun 30, 2027

NCT ID

NCT04603495

About Pelabresib + Ruxolitinib + Placebo

Pelabresib + Ruxolitinib + Placebo is a phase 3 stage product being developed by Novartis for Myelofibrosis. The current trial status is active. This product is registered under clinical trial identifier NCT04603495. Target conditions include Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis.

What happened to similar drugs?

2 of 18 similar drugs in Myelofibrosis were approved

Approved (2) Terminated (3) Active (13)

✅ruxolitinib + panobinostatNovartisApproved

✅INC424NovartisApproved

🔄Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3

🔄Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3

❌Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3

🔄INC424NovartisPhase 3

🔄Pelabresib + Ruxolitinib + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07357727	Phase 3	Recruiting	Apr 15, 2026	Dec 27, 2030	Primary Myelofibrosis (PMF)
NCT04603495	Phase 3	Active	Apr 9, 2021	Jun 30, 2027	Myelofibrosis

Competing Products

20 competing products in Myelofibrosis

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Nusivertib + Ruxolitinib + Momelotinib	Sumitomo Pharma	Phase 1/2	39
Ruxolitinib + Navitoclax	AbbVie	Phase 2	35
ABBV-744 + Navitoclax + Ruxolitinib	AbbVie	Phase 1	33
Placebo for Navitoclax + Ruxolitinib + Navitoclax	AbbVie	Phase 3	40
Mivebresib + Navitoclax + Ruxolitinib	AbbVie	Phase 1	21
Navitoclax + Venetoclax	AbbVie	Pre-clinical	26
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)	AbbVie	Phase 3	44
NS-018 + Best Available Therapy	Nippon Shinyaku	Phase 2	27
AZD1480	AstraZeneca	Phase 1	29
Bomedemstat	Merck	Phase 2	31
Peginterferon alfa-2a	Merck	Phase 2	27
Bomedemstat	Merck	Phase 1/2	32
MBG453 + NIS793 + Spartalizumab + Decitabine	Novartis	Phase 1	21
PIM447 + Ruxolitinib + LEE011	Novartis	Phase 1	29
LDE225 + INC424	Novartis	Phase 1/2	32
Imatinib mesylate	Novartis	Phase 2	35
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793	Novartis	Phase 1/2	24
Ruxolitinib + Ruxolitinib Placebo	Novartis	Phase 3	32
Ruxolitinib	Novartis	Pre-clinical	30